Biopharmaceutical manufacturing boost part of new UK government budget

In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). 

The UK chancellor of the exchequer Rachel Reeves debuted the Labour Party’s new budget on Wednesday October 30, 2024, in which up to GBP£520 million will be used as capital grants to invest in drug manufacturing and medical technologies. The LSIMF comes as part of the UK’s safeguarding practices against healthcare emergencies, as well as to boost and capitalise on the nation’s life science industry. In order to qualify for these capital grants, interested company projects must cost at least GBP£8 million. The national budget also included boosted funds for the UK’s National Health Service (NHS) and for the National Institute for Health Research, with promises to grant greater investment in R&D.  

The budget comes on the heels of calls from the Association of the British Pharmaceutical Industry (ABPI) for the UK government to lay out solid plans for national healthcare investment. A ‘Manifesto for Investment, Health and Growth’ was released by the ABPI ahead of the UK summer elections a few months ago calling for each political party to deliver better health and equity to NHS patients, bringing manufacturing roles back to the UK, and increasing accessibility to new drugs in clinical trials, among others. 

In a statement regarding the national budget, Chief Executive of the ABPI Richard Torbett commented, “Despite the tough fiscal environment, today’s budget is a clear indication that the government sees life sciences at the heart of its growth mission.” 

Source: 

UK’s Labour Party unveils £520M innovative manufacturing fund as part of life-sci-heavy budget [Accessed November 7, 2024] https://www.fiercepharma.com/pharma/uks-labour-party-unveils-ps520m-innovative-manufacturing-fund-part-life-sci-heavy-budget